文献速递胸部CT

将CT淋巴结大小作为N1描述符纳入肺癌临床N分期

Incorporating Lymph Node Size at CT as an N1 Descriptor in Clinical N Staging for Lung Cancer.
PubMed 文献 · Radiology · 2025-01-01

本研究为回顾性研究,纳入2013年1月至2021年12月接受肺叶或全肺切除术的肺癌患者,分为开发队列(2016-2021年)和验证队列(2013-2015年),基于CT上最大临床阳性淋巴结短轴直径确定大淋巴结的最佳截断值为15 mm,大淋巴结为总生存期的独立危险因素(HR 1.54),在cN1类别中cN1-大淋巴结组死亡风险高于cN1-非大淋巴结组,C-index从0.50提高到0.60(开发队列)和0.58(验证队列)。

要点

  • CT上最大临床阳性淋巴结短轴直径≥15 mm定义为大淋巴结。
  • 大淋巴结是总生存期的独立危险因素(HR 1.54)。
  • cN1-大淋巴结组死亡风险高于cN1-非大淋巴结组。

核心结论

  • 定义大淋巴结短轴直径截断值为15 mm是肺癌N1临床分期的有效描述符。

研究设计与样本

  • 回顾性研究,开发队列3426例(2016-2021年),验证队列1327例(2013-2015年),均接受肺叶或全肺切除术,基于CT最大临床阳性淋巴结短轴直径。

诊断标准与关键数值

  • 大淋巴结截断值为短轴直径15 mm。
  • 大淋巴结为总生存期的独立危险因素(HR 1.54;95% CI:1.10,2.16;P = .01)。
  • 开发队列中cN1-大淋巴结组较cN1-非大淋巴结组死亡风险更高(HR 2.82;95% CI:1.73,4.58;P < .001)。
  • 验证队列中cN1-大淋巴结组较cN1-非大淋巴结组死亡风险更高(HR 2.29;95% CI:1.34,3.92;P = .002)。
  • 大淋巴结描述符改善cN1类别内预后区分度,开发队列C-index从0.50到0.60(P < .001),验证队列从0.50到0.58(P = .006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The ninth edition of the TNM classification for lung cancer revised the N2 categorization, improving patient stratification, but prognostic heterogeneity remains for the N1 category. Purpose To define the optimal size cutoff for a bulky lymph node (LN) on CT scans and to evaluate the prognostic value of bulky LN in the clinical N staging of lung cancer. Materials and Methods This retrospective study analyzed patients who underwent lobectomy or pneumonectomy for lung cancer between January 2013 and December 2021, divided into development (2016-2021) and validation (2013-2015) cohorts. The optimal threshold for a bulky LN was defined based on the short-axis diameter of the largest clinically positive LN at CT. Prognostic differences according to presence of bulky LN in cN1 category for overall survival (OS) were evaluated using multivariable Cox analysis. Survival discrimination was assessed using the Harrell concordance index (C-index). Results A total of 3426 patients (mean age, 64.0 years ± 9.3 [SD]; 1837 male) and 1327 patients (mean age, 63.0 years ± 9.7; 813 male) were included in the development and validation cohorts, respectively. The cutoff size for a bulky LN was established at 15 mm, and the presence of bulky LN was an independent risk factor for OS (hazard ratio [HR], 1.54; 95% CI: 1.10, 2.16; P = .01). In the development and validation cohorts, the cN1-bulky group had higher mortality risk than the cN1-nonbulky group (HR, 2.82 [95% CI: 1.73, 4.58; P < .001]; 2.29 [95% CI: 1.34, 3.92; P = .002], respectively). The bulky LN descriptor improved prognostic discrimination within the cN1 category compared with the current staging (C-index from 0.50 to 0.60 and to 0.58 in the development and validation cohorts [P < .001, P = .006], respectively]). Conclusion Defining bulky LN with a size cutoff of 15 mm was an effective descriptor in the clinical staging of N1 lung cancer. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Horst in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ahn Y, Lee SM, Choe J, et al. Incorporating Lymph Node Size at CT as an N1 Descriptor in Clinical N Staging for Lung Cancer. Radiology. 2025. PMID: 39835984. doi:10.1148/radiol.241603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。